Comparative Pharmacology
Head-to-head clinical analysis: ACUVAIL versus NEVANAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVAIL versus NEVANAC.
ACUVAIL vs NEVANAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes. This reduces ocular inflammation and pain.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, primarily COX-2, reducing prostaglandin synthesis and thereby suppressing ocular inflammation and pain.
1 drop in the affected eye 4 times daily.
One drop of 0.1% ophthalmic suspension instilled into the affected eye(s) three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 46 minutes in the aqueous humor following ocular administration in humans.
The terminal elimination half-life of nepafenac is approximately 12.5 hours in plasma, while its active metabolite amfenac has a half-life of about 24 hours. This supports twice-daily dosing.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for <10%.
Nepafenac is extensively metabolized, primarily via hydrolysis to amfenac. Renal excretion accounts for approximately 85% of the administered dose, with about 13% excreted as unchanged nepafenac and amfenac in urine. Fecal elimination is minimal.
Category C
Category C
NSAID Ophthalmic
NSAID Ophthalmic